An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

Inclusion Criteria:

1. Male or female adults ≥ 18 years of age.

2. Diagnosis of chronic plaque-type psoriasis for at least 6 months

3. Moderate to Severe plaque psoriasis as defined by BSA ≥10 PASI ≥12 IGA ≥3

4. Able to give written informed consent prior to performance of any study relatedprocedures

5. Subject is able to attend Narrowband UVB phototherapy sessions three times a week andall other protocol specified visits

6. Subject must be in general good health (except for psoriasis) as judged by theInvestigator, based on medical history, physical examination.

Exclusion Criteria:

1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic,and/or guttate psoriasis) or drug induced psoriasis

2. History of photosensitivity

3. Subject has used ustekinumab and/or anti-IL-17 biologic therapy within 24 weeks orother experimental or commercially available biologic immune modulator(s) within 12weeks prior to the first IP dose.

4. Use of any investigational drug within 4 weeks prior to randomization, or within 5pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).

5. Use of oral systemic medications for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin,apremilast and cyclosporine).

6. Patient used topical therapies to treat within 2 weeks of the Baseline Visit (includes, but not limited to, topical corticosteroids, vitamin D analogs, orretinoids).

7. Initiated within 3 months, planned initiation of, or changes to, concomitantmedications that could affect psoriasis vulgaris (e.g. beta blockers, antimalarialdrugs, lithium, ACE inhibitors ) during the trial

8. Active infections requiring antibiotics in the 2 weeks prior to Baseline

9. Patient received UVB phototherapy within 4 weeks of Baseline.

10. Patient received PUVA phototherapy within 4 weeks of Baseline.